Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Cash from Operations (2019 - 2025)

IDEAYA Biosciences' Cash from Operations history spans 7 years, with the latest figure at 90496000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 25.61% year-over-year to 90496000.0; the TTM value through Dec 2025 reached 71098000.0, up 71.28%, while the annual FY2025 figure was 71098000.0, 71.28% up from the prior year.
  • Cash from Operations for Q4 2025 was 90496000.0 at IDEAYA Biosciences, down from 142214000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 142214000.0 in Q3 2025 and bottomed at 121655000.0 in Q4 2024.
  • The 5-year median for Cash from Operations is 26004000.0 (2022), against an average of 28843000.0.
  • The largest annual shift saw Cash from Operations plummeted 412.27% in 2024 before it surged 388.85% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 16657000.0 in 2021, then tumbled by 40.3% to 23370000.0 in 2022, then fell by 1.62% to 23748000.0 in 2023, then tumbled by 412.27% to 121655000.0 in 2024, then increased by 25.61% to 90496000.0 in 2025.
  • Per Business Quant, the three most recent readings for IDYA's Cash from Operations are 90496000.0 (Q4 2025), 142214000.0 (Q3 2025), and 62474000.0 (Q2 2025).